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Review
Zinc in Multiple Sclerosis: A Systematic
Review and Meta-Analysis
Mikkel Bredholt1 and Jette Lautrup Frederiksen1
Abstract
In the last 35 years, zinc (Zn) has been examined for its potential role in the disease multiple sclerosis (MS). This review gives
an overview of the possible role of Zn in the pathogenesis of MS as well as a meta-analysis of studies having measured Zn in
serum or plasma in patients with MS. Searching the databases PubMed and EMBASE as well as going through reference lists in
included articles 24 studies were found measuring Zn in patients with MS. Of these, 13 met inclusion criteria and were
included in the meta-analysis. The result of the meta-analysis shows a reduction in serum or plasma Zn levels in patients with
MS with a 95% CI of [3.66, 0.93] and a p value of .001 for the difference in Zn concentration in mM. One of six studies
measuring cerebrospinal fluid, Zn levels found a significant increase in patients with MS with controls. The studies measuring
whole blood and erythrocyte Zn levels found up to several times higher levels of Zn in patients with MS compared with
healthy controls with decreasing levels during attacks in relapsing-remitting MS patients. Future studies measuring serum or
plasma Zn are encouraged to analyze their data through homogenous MS patient subgroups on especially age, sex, and
disease subtype since the difference in serum or plasma Zn in these subgroups have been found to be significantly different.
It is hypothesized that local alterations of Zn may be actively involved in the pathogenesis of MS.
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Introduction
Multiple sclerosis (MS) is categorized as an autoimmune
disease and is potentially one of the most common causes
of neurological disability in young adults. The disease can
generally be divided into three clinical subtypes: relap-
sing-remitting MS (RRMS), secondary progressive MS
(SPMS), and primary progressive MS (PPMS), although
studies question the homogeneity of the disease with espe-
cially PPMS having a diﬀerent clinical course and a
seemingly diﬀerent pathogenesis (Foong et al., 2000;
Lassmann et al., 2001). Formation of the sclerotic pla-
ques of which the disease gets its name represents the end
stage of a process involving inﬂammation, demyelination
and remyelination, oligodendrocyt depletion, and astro-
gliosis as well as neuronal and axonal degeneration. The
inﬂammation may impede the proper propagation in
three ways: inﬂammatory mediators directly impede con-
duction in intact axons, the demyelination of axons by
microglia thereby compromising the ability of proper
conduction of the axon, or axonal transection
(Compston and Coles, 2008). The etiology of the disease
is not known though it is clear that it is caused by a
complex interplay between genes and environment
(Sadovnick and Ebers, 1993). The strongest genetic asso-
ciations have been found to be in the major histocompati-
bility complex with HLA-DRB1 to have the strongest
eﬀect (Patsopoulos et al., 2013). Other genes have been
identiﬁed as well, with Zn-ion binding genes involved in
the expression of IFN-c being able to predict the clinical
outcome in RRMS patients with 88.9% accuracy
(Achiron et al., 2007).
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Zinc
Zn is an essential trace element for all organisms, and Zn
level alterations have consequences on particularly the
nervous, the reproductive and the immune system.
Being a cofactor of more than 300 enzymes including
matrix metalloproteinases (MMPs) and a component of
an even greater amount of proteins including Myelin
Basic Protein, Zn emphasizes its important role in
human health (Vallee and Falchuk, 1993; Berlet et al.,
1994). Zn’s plasma concentration is 12 to 16 mM and is
nearly completely protein-bound with 80% bound to
albumin and 20% bound to a2-macroglobulin (Scott
and Bradwell, 1983). Zn is an abundant metal in the
brain and is mainly found in presynaptic vesicles in neu-
rons. With Zn deﬁciency being able to induce apoptosis in
neural cells as well as high levels of Zn being neurotoxic,
it is clear that eﬃcient Zn homeostasis in the brain is
important (Yokoyama et al., 1986; Adamo et al., 2010).
Zn and the immune system. Zn deficiency decreases several
functions in the immune system including peripheral T-cell
count, T-helper cell function, cytotoxic T-cell activity, NK-
cell activity, and macrophage and neutrophil functions (Rink
and Gabriel, 2000). Even though these eects seem contra-
dictory of Zn deficiency being involved in the exacerbation
of MS as an autoimmune disease, a study by Kitamura et al.
(2006) showed that the intracellular reduction of Zn is an
activator of dendritic cell maturation resulting in increased
cell-surface expression of MHC and costimulatory mol-
ecules, potentially resulting in unwanted activation of
T-cells and T-cell mediated autoimmunity. Elevation of Zn
alone can induce the expression of the high-anity receptor
for IL-2, important for the proliferation and dierentiation of
CD4þ and CD8þ lymphocytes to eector-cells, as well as
being able to trigger microglia activation, the resident
immune cell of the CNS important in the pathogenesis of
MS (Tanaka, 1989; Higashi et al., 2011).
Zn and MMPs. MMPs are a group of proteases all dependent
of Zn for their proteolytic activity. They are involved in
remodeling of the extracellular matrix and modifying cell–
matrix interactions (Murphy and Nagase, 2008). Their pro-
teolytic substrates include myelin basic protein, components
of the blood–brain barrier (BBB), and neural/glial antigen 2
(NG2), important for proper remyelinisation in the CNS,
giving them a potential important role in both the pathogen-
esis of MS as well as in the development of new treatments
for MS (Chandler et al., 1995; Larsen et al., 2003; Ram
et al., 2006). Studies measuring MMP levels in patients
with MS have shown that several MMPs are altered (Bar-
Or et al., 2003). A study by Kanesaka et al. (2006) showed
that serum MMP-3 was significantly higher within 1 month
before a relapse compared with the remission-phase serum
levels of RRMS patients, suggesting a role in disease exacer-
bation through increased disruption of the BBB. The studies
implicate an important role of especially MMP-9 in MS with
results showing increased serum and cerebrospinal fluid (CSF)
levels of MMP-9 in patients with MS compared with healthy
controls (HCs) and increased MMP-9 CSF levels in RRMS
patients during active disease compared with stable RRMS
patients (Liuzzi et al., 2002). The involvement of MMP-9 in
MS is further emphasized in a study by Correale and Bassani
(2003) showing that MMP-9 levels in clinical isolated syn-
drome (CIS) patients that developed clinically definite MS
was significantly higher than in those who did not.
The altered levels of MMPs may inﬂuence MS patho-
genesis in several ways. First of MMPs may mediate
migration of autoreactive lymphocytes across the BBB
by their proteolytic degradation of the subendothelial
basement membrane. This is shown by Leppers et al.
(1995) in an in vitro model of the BBB with increasing
levels of MMPs to result in increased migration of T-cells.
Second, MMPs may contribute to myelin breakdown
because of their proteolytic activity against myelin basic
protein as well as contribute to epitope spreading of
these. Even though MMP levels are highest during
exacerbation of MS, it might also be important in the
remission of the disease, as Larsen et al. (2003) showed
by impairing remyelination in mice lacking MMP-9
because of their failure to clear NG2, a proteoglycan
retarding the maturation and diﬀerentiation of oligo-
dendrocytes. With all of the MMPs being Zn dependent
for their proteolytic activity, local alterations in Zn level
will most likely inﬂuence the eﬀect of MMPs.
Zn altering therapy. With Zn’s role in MS yet to be fully
understood, it is still unclear whether altering Zn levels is
helpful in inhibiting disease exacerbation. Studies of Zn sup-
plementation have shown reduced T-cell activation and pro-
liferation thereby being a promising approach in a future
therapeutic manner (Stoye et al., 2012). Although a recent
study showed no improvements of neurological signs in
patients with MS compared with the placebo group after
12 weeks of Zn supplementation (Salari et al., 2015), another
approach by Choi et al. (2013) with redistributing Zn in the
body with Clioquinol (a Copper or Zn chelator) has shown
promising results in the animal model of MS: Experimental
Autoimmune Encephalitis (EAE). The study showed sup-
pression of demyelination, reduced infiltration of encephali-
togenic immune cells, inhibited BBB disruption, reduced
MMP-9 activation and reduced clinical score of EAE after
treatment with Clioquinol.
With the study by Wong et al. (1980) showing signiﬁ-
cantly reduced plasma Zn levels in patients with MS,
studies have been performed since then studying Zn
levels in patients with MS to unravel this potential role
of Zn in the etiology or pathogenesis of MS.
As the amount of studies studying Zn levels in patients
with MS accumulate and studies, with especially serum or
plasma Zn levels showing heterogeneity in their results,
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a systematic review and a meta-analysis are performed to
create an overview of the published results of Zn measur-
ing studies in patients with MS.
Methods
Search Strategy and Inclusion Criteria
The literature-search was done in PubMed and
EMBASE. The search proﬁle for PubMed consisted of
‘‘Zinc AND ‘multiple sclerosis’’’ giving 133 hits and ‘Zinc
AND ‘optic neuritis’’’ giving 14 hits with no overlap. The
search proﬁle for EMBASE consisted of ‘‘Zinc AND
*multiple sclerosis’’ giving 141 hits and ‘‘Zinc AND
*optic neuritis’’ giving 3 hits with no overlap. For both
search proﬁles, all titles got examined and abstracts read
of those maybe being relevant. Reference lists of retrieved
studies were searched for additional reports. Inclusion
criteria were studies having measured Zn levels in patients
with MS.
Meta-Analysis Inclusion Criteria
Inclusion criteria for studies in the meta-analysis were
studies with results on serum or plasma Zn levels given
in meanSD or SEM. With studies only giving results of
subgroups, the weighted grand mean of the patients with
MS included in the study was calculated, and the com-
posite SD was found by analysis of variance.
Meta-Analysis Statistical Method
Mean diﬀerence as well as 95% conﬁdence intervals (CIs)
were calculated using a random eﬀects model instead of
the ﬁxed eﬀect model, as heterogeneity between studies
are expected. Random eﬀect models assume and account
for variable underlying eﬀects in estimates of uncertainty,
including both within-study and between-studies variance
(Borenstein et al., 2009). The eﬀect sizes were calculated
with Review Manager (RevMan) [Computer program]
Version 5.3., Copenhagen: The Nordic Cochrane
Centre, The Cochrane Collaboration, 2014.
Results
Of the 291 hits and of the reference lists in retrieved
studies, 24 articles were found to study Zn levels in
patients with MS, of which 19 had measured serum or
plasma Zn levels and 6 had measured CSF Zn levels.
A total of 11 studies were found to study other param-
eters of Zn or having data on subgroup analysis on Zn
levels. The results of the 19 studies measuring serum or
plasma Zn levels in patients with MS are summarized in
Table 1. The results of the six studies measuring CSF Zn
levels in patients with MS are summarized in Table 2, and
the conclusions of the studies measuring other parameters
or subgroup analyses on Zn levels are reported in Table 3.
Results given in other units were converted to mmol/L
with (Zn¼ 65.38 g/mol) (Wieser Michael et al., 2013)
and results given with SEM were converted back to SD.
It was found by Foley et al. (1968) that plasma Zn was
16% higher than in serum, although later studies have
shown no signiﬁcant or only very little diﬀerence
between serum and plasma Zn concentrations, therefore,
making them comparable (Kosman and Henkin, 1979;
Kasperek et al., 1981; Kiilerich et al., 1981; Chen et al.,
1986).
Meta-Analysis
Of the 19 studies measuring serum or plasma Zn levels in
patients with MS, 13 studies met inclusion criteria. The
results of the meta-analysis is given in forest plot format
in Figure 1 showing a signiﬁcant diﬀerence in serum or
plasma Zn levels in patients with MS versus HCs with a
95% CI of [3.66, 0.93] and p¼ .001. An I2 value on
97% shows high heterogeneity in the meta-analysis.
Discussion
The present meta-analysis of studies measuring serum or
plasma Zn levels in MS reports a signiﬁcant reduction in
overall serum or plasma Zn levels in patients with MS,
with studies reporting both lowered, no diﬀerence and
increased serum or plasma Zn levels. Most of the studies
included were in the non-signiﬁcant range.
The great variance in the outcome of the studies might
be explained by the heterogeneity of the serum or plasma
Zn levels in patients with MS. The studies by Wong et al.
(1980) and Palm and Hallmans (1982) show that the
decrease in serum or plasma Zn with age in patients
with MS does not correlate with the higher decrease
seen in HCs with age. Studies including mostly old
patients with MS may ﬁnd no signiﬁcant diﬀerence
between MS and HCs even though it is possible that
the younger patients with MS would show a signiﬁcant
diﬀerence. Therefore, it is not only enough for future
studies to match patients with MS on age but also to be
aware that a high mean age of patients with MS in the
study might obscure a greater signiﬁcant diﬀerence
between younger patients with MS and HCs.
The study by Palm and Hallmans (1982) shows that
the diﬀerence in correlation of decreasing serum or
plasma Zn level with age between patients with MS and
HCs is only found in males, as well as disease stage and
degree of malignancy only having signiﬁcant diﬀerences
in Zn levels in male patients with MS. Therefore, some of
the results showing no diﬀerence in serum or plasma Zn
levels might be because of the low men or female MS
patient ratio found in most of the studies. Because of
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the prevalence ratio of female versus men aﬀected by MS
being more than two to one, studies randomly selecting
participants out of a MS population might ﬁnd no sig-
niﬁcant results even though one is present in the male
population of the participants. The results of Palm and
Hallmans (1982) and Ghazavi et al. (2012) study not only
emphasize the importance of keeping results between gen-
ders separated but also that the diﬀerent subtypes of MS
might have diﬀerent alterations in serum or plasma Zn.
Only the slowly progressive subgroup had signiﬁcantly
lowered Zn level in the study done by Palm and
Hallmans and in the study done by Ghazavi et al., the
patients with SPMS had signiﬁcantly lowered Zn levels
compared with the patients with RRMS. Future studies
on serum or plasma Zn should, therefore, have in mind
that uncritical mixing of patients with MS in studies on
age, sex, disease subtype, duration of disease, and degree
of disability might conceal a greater signiﬁcant diﬀerence
Table 1. Serum or Plasma Zinc in Multiple Sclerosis Versus Healthy Controls.
Study Body fluid MS (N) HC (N)
Mean SD
MS
Mean SD
HC p Conclusion
Wong et al. (1980) Plasma 26 39 n/a n/a <.0001 Significantly lowered in
MS (Mþ F) if
age< 50 years
Weismann et al. (1982) Plasma 10 n/a 13 n/a n/a .01 Correlation between
low plasma Zn and
low albumin in MS
Palm and Hallmans (1982) Serum M: 21 M: 21 13.0 1.9 14.8 1.6 <.001 Significantly lowered
in MS (Mþ F)
F: 29 F: 29 12.1 2.1 13.2 1.6 .05
Dore-Duffy et al. (1983) Plasma M: 18 M: 30 14.8 3.2 12.5 1.8 <.01 Only significantly higher
in MS males
F: 50 F: 30 12.3 1.6 11.6 1.5 NS NS for MS (Mþ F)
T: 68 T: 60 12.9 2.4 12.0 1.8 NS
Ho et al. (1986) Plasma 45 23 13.6 3.1 13.5 1.5 NS NS
Kapaki et al. (1989) Serum 15 28 15.8 2.1 16.8 2.9 NS NS
Smith et al. (1989) Plasma 14 33 15.7 3.0 15.3 0.1 NS NS
Forte et al. (2005) Plasma 60 60 91.7 22.8 100.6 15.5 .05 Significantly lowered in MS
Alimonti et al. (2007) Serum 60 124 n/a n/a .0003 Significantly lowered
in MS (Mþ F)
Masoud and
Fakharian (2007)
Serum M: 7 M: 7 12.0 1.6 16.7 1.6 <.0001 Significantly lowered
in MS (Mþ F)
F: 28 F: 28 13.3 2.1 16.8 1.1 <.0001
T: 35 T: 35 13.1 2.1 16.8 1.3 <.0001
Gellein et al. (2008) Plasma 9 16 5.1 0.7 5.2 0.9 NS NS
Harbige et al. (2011) Plasma 21 9 13.5 2.5 13.1 2.0 NS NS
Ghazavi et al. (2012) Serum M: 17 M: 22 5.0 3.3 20.2 6.1 n/a Significantly lowered
in MS
F: 43 F: 38 7.2 5.4 20.2 7.0 n/a
T: 60 T: 60 6.1 4.9 19.5 6.5 <.0001
Al-Zubaidi (2012) Serum 32 32 16.3 3.3 23.0 0.5 <.0001 Significantly lowered
in MS
Nasrabadi et al. (2012) Plasma 40 20 n/a n/a NS NS
Sedighi et al. (2013) Serum 58 39 36.7a n/a 40.9a n/a .249 NS
Kazmierczak et al. (2014) Plasma 11 38 n/a n/a .8 NS
Giacoppo et al. (2014) Plasma 41 23 40.0 9.6 43.0 8.7 NS NS
Ghoreishi et al. (2015) Serum 50 50 1.1 0.06 0.7 0.07 <.005 Significantly higher in MS
Note. Mean and SD are given in mM. Different units have been converted to mM with (Zn¼ 65.38 g/mol), and SEM has been converted to SD. n/a¼ data not
available; M¼males; F¼ females; T¼ total; NS¼ non-significant; HC¼ healthy controls..
aUnit of measurement not available.
4 ASN Neuro
in subgroups of the study. It was examined whether it was
possible to analyze the correlation between Zn levels and
MS in regard to age or sex of patients and HC, although
too few studies had their results presented in a way for
this to be possible.
Not all studies included in the meta-analysis men-
tioned the proper precautions done to prevent the inﬂu-
ence of the many confounders in serum or plasma Zn
level analysis. As shown by Rea (1989), serum Zn levels
are dependent on age and sex, though sex and age match-
ing was not mentioned in 5 out of the 13 studies included
(Kapaki et al., 1989; Smith et al., 1989; Gellein et al.,
2008; Harbige et al., 2011; Giacoppo et al., 2014). As
diﬀerent medication here including Prednisolone,
INF-ß1 a-treatment and oral contraceptives alter serum
or plasma Zn levels, treatment with these should be
paused before blood sampling in both patients and HCs
or be an exclusion criterion (Briggs et al., 1971; Fallah
et al., 2009; Al-Zubaidi, 2012). Precautions done against
the possible confounding factor of medication in patients
and HCs were only mentioned in 7 out of the 13 studies
included (Palm and Hallmans, 1982; Dore-Duﬀy et al.,
1983; Ho et al., 1986; Kapaki et al., 1989; Forte et al.,
2005; Al-Zubaidi, 2012; Ghazavi et al., 2012).
The confounders mentioned so far are the most
important in regard to the meta-analysis. The diﬀerences
in the procedure of blood sampling and Zn analysis will
not have a great impact on the result of the meta-analysis
as long as the procedure has been the same between
patients with MS and HCs and will mostly increase the
heterogeneity between the studies. This is because of the
use of the random eﬀects model that also assumes and
accounts for the regional diﬀerences in Zn levels (Iyengar,
1987). This is also the reason why the results of Forte
et al. (2005), Gellein et al. (2008), Giacoppo et al.
(2014), and Goreishi et al. (2015) were included, even
though their results of plasma Zn are very diﬀerent com-
pared with the other studies. The low levels of serum or
plasma Zn recorded in Gellein et al. and Goreishi et al.
should result in severe Zn deﬁciency symptoms in both
patients and HCs. Since the authors does not mention
any reports of Zn deﬁciency as well as results in the
four studies report Zn concentrations in the same levels
for both patients and HCs, it is assumed that the low
levels is a consequence of the analysis used in assessing
the Zn concentration. It should be noted that the measur-
ing of serum or plasma Zn levels includes many confoun-
ders here including circadian and postprandial
ﬂuctuations (Markowitz et al., 1985; Wallock et al.,
1993) as well as being prone to contamination through
hemolysis in blood samples and prolonged stasis while
the blood sample is taken (Kiilerich et al., 1980).
Information about precautions against these confounders
are lacking in most studies.
As most of the studies included reported no signiﬁcant
diﬀerence in serum or plasma Zn levels in patients with
MS, the risk of publication bias to have an inﬂuence on
the outcome of the meta-analysis is assumed to be low.
Of the six studies measuring CSF Zn levels, the study
by Linke et al. (1977) found a signiﬁcant increase, though
none of the later studies could ﬁnd a signiﬁcant diﬀerence
between patients with MS and controls. It is hard to
Table 2. Cerebrospinal Fluid Zinc in Multiple Sclerosis Versus Controls.
Study Body fluid MS (N) C (N)
Mean SD
MS
Mean SD
HC p Conclusion
Linke et al. (1977) CSF 40 24a 3.12 2.20 1.12 0.66 <.001 Significantly higher
in MS.
Palm and Hallmans (1982) CSF M: 11 M: 11b 0.14 0.03 0.17 0.05 NS NS
F: 18 F: 18b 0.15 0.06 0.16 0.04 NS
Ho et al. (1986) CSF MS active: 10 9c 0.55 0.38 0.55 0.45 NS NS
MS stable: 10 0.50 0.38 NS NS
Kapaki et al. (1989) CSF 15 28d 0.53 0.30 0.53 0.08 NS NS
Melo et al. (2003) CSF 18 19e 0.29 0.13 0.36 0.21 NS NS
Gellein et al. (2008) CSF 9 16f 0.33 0.09 0.38 0.15 NS NS
Note. Mean and SD are given in mM. Different units have been converted to mM (Zn¼ 65.38 g/mol), and SEM has been converted to SD. M¼males;
F¼ females; T¼ total; NS¼ non-significant; C¼ controls; Active¼ during attack.
aPatients in which cerebral disease has been excluded and with no deviation from standard levels.
bCSF samples from 18 HCs and the rest from patients with psychoneurosis, tension headache, and other pain syndromes in whom neurological examination
failed to define an organic CNS lesion.
cPatients with other neurological diseases as Guillain-Barre disease, myasthenia gravis, central nervous system lupus erythematosus, bacterial meningitis,
herpes encephalitis, amyotrophic lateral sclerosis, and pseudotumor cerebri.
dPatients cleared for neurological disease and with no sign of infection, liver disease, renal disease, tuberculosis, or alcoholism.
ePatients with no known neurological disorder or deficit.
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conclude anything on those studies since the high SD in
most of the studies report big variance between the meas-
urements and combined with the small number of partici-
pants it is highly unlikely to be able to ﬁnd a statistical
diﬀerence. The big SD and the variance in Zn levels
between the studies may be explained be the small
amount of Zn present in CSF ﬂuid, making the measure-
ments very susceptible to contamination during the ana-
lysis. It should be noted although that of the ﬁve studies
done after Linke et al., the mean were in MS found either
to be the same or slightly lower than in the control group.
Beside the signiﬁcant decrease in plasma or serum Zn
levels in patients with MS compared with HCs other
interesting ﬁndings in regard to Zn’s potential inﬂuence
on MS pathogenesis so far is the alterations of whole
blood Zn of patients with MS as reported by several
studies as well as the increase in RBC Zn. Whole blood
Zn was found to be higher in patients with MS, with male
patients with MS having signiﬁcantly higher levels com-
pared with female patients and relapsing cases having
increased levels as well compared with chronic cases as
shown by Rieder et al. (1983). Some of the explanation
for this increase is elaborated in the studies by Dore-
Duﬀy et al. (1983) and Ho et al. (1986) showing increased
amount of Zn in the lipid-soluble fraction of RBC mem-
branes with results showing up to 3 to 4 times higher Zn
in membranes of RBCs in patients with MS as well as an
increased amount of Zn bound to a2-macroglobulin.
With no diﬀerence in plasma Zn as well as cytoplasmic
RBC Zn, they suggest that patients with MS have altered
compartmentalization of Zn.
With the study by Ho et al. (1986) showing a dramatic
reduction of these Zn levels during the exacerbation of an
MS attack and slowly increasing Zn levels during the
remission, together with the promising therapeutic eﬀect
on EAE by altering Zn levels with Clioquinol, alterations
in local Zn levels may play an important role in the
pathogenesis of MS. Future studies should examine
whether the alteration in compartmentalization in Zn is
only present in RBC or is also present in lymphocytes or
other immune cells in patients with MS.
Summary
A systematic review of Zn potential role in the pathogenesis of MS
as well as a meta-analysis showing significantly lowered Zn levels
in MS patients compared with healthy controls.
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